ValuentumAd

Official PayPal Seal

Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 22, 2019
Johnson & Johnson Overcoming Pharma Pricing Pressure
Image Source: Johnson & Johnson fourth quarter presentation. Johnson & Johnson’s ‘Pharmaceutical’ segment continues to deliver top-line growth despite ongoing headwinds related to net price decreases in the US pharma space. The company remains one of our favorite dividend growth ideas as its higher-growth ‘Pharmaceutical’ segment is augmented by a solid ‘Consumer’ business and improving ‘Medical Devices’ business.
Jan 14, 2019
Value Trap, More Volatility; We're Waiting and Watching
Image shown: The decision to remove GE from the simulated newsletter portfolios when we did may have been our best call yet. In this note, let's talk about the importance of reading Value Trap, learn why we've gone "fully invested," talk a little bit about put options, learn some of the intricacies of the Valuentum process, find out where to find VBI rankings to download and sort, and talk about some of our recently-highlighted ideas in the simulated newsletter portfolios. No Changes to Simulated Newsletter portfolios.
Jan 9, 2019
The Intricacies of the Valuentum Process
Let’s take a quick overview of the Valuentum processes for capital appreciation and dividend growth with a discussion of how we use the Valuentum Buying Index and the Dividend Cushion ratio.
Jan 3, 2019
Fully-Invested? Why? Thoughts on Microsoft and Eli Lilly, and Celgene
Our methodology is really easy to understand once you get to know the things we’re looking at. There’s also some subjectivity in how we implement our thoughts in the simulated newsletter portfolios, and please stop calling what we do advice. We’re a financial publisher. While we’re at it, let’s talk a bit about Microsoft, Eli Lilly, and Celgene through the lens of our methodology.
Jan 2, 2019
Here It Comes… Apple’s Shot Across the Bow
Image Source: Tinh tế Photo. Apple surprised the market by issuing first-quarter 2019 guidance below expectations. The company pointed to weakness in China as the main culprit. We continue to expect heightened levels of volatility, and investors in key American icons that might be impacted by consumer backlash in China should be on high alert. No changes to the simulated newsletter portfolios as a result of the news.
Dec 10, 2018
In the News: Generic Drug Price Fixing and Apple’s Legal Battle in China
An investigation into pricing practices in the generic drug industry has substantially expanded, and implications may be far more widespread than initially expected. Meanwhile, Apple is fighting a preliminary order that will ban the sale of its iPhones that utilize certain software.
Dec 7, 2018
In the News: OPEC Production Cut Agreement, Jobs and Consumer Sentiment, and Altria Gets in the Pot Game
Let’s take a look at some major headlines. Topics include OPEC’s production cut, the recent jobs and consumer sentiment reports, and Altria’s investment in a marijuana company.
Dec 7, 2018
Dividend Increases/Decreases for the Week Ending December 7
Let's take a look at companies that raised/lowered their dividend this week.
Nov 1, 2018
Adding Xilinx to the Dividend Growth Newsletter Portfolio
We’re adding Xilinx to the simulated Dividend Growth Newsletter portfolio. The company generates a hefty Dividend Cushion ratio of 3.3!
Oct 25, 2018
Microsoft Reports Strong Start to Fiscal Year
Image Source: Mike Mozart. Simulated Dividend Growth Newsletter portfolio idea Microsoft reported impressive results in its fiscal first quarter, and its robust free cash flow generation continues to pave the way for future dividend increases.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.